scholarly journals Celiac plexus block increases quality of life in patients with pancreatic cancer

2019 ◽  
Vol Volume 12 ◽  
pp. 307-315
Author(s):  
István Molnár ◽  
Gabriella Hegyi ◽  
Lajos Zsom ◽  
Christine Saahs ◽  
Jan Vagedes ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Celiac Plexus ◽  
Celiac Plexus Block ◽  
Plexus Block

scholarly journals Effect of Neurolytic Celiac Plexus Block on Pain Relief, Quality of Life, and Survival in Patients With Unresectable Pancreatic Cancer

JAMA ◽  
2004 ◽  
Vol 291 (9) ◽  
pp. 1092 ◽  
Author(s):  
Gilbert Y. Wong ◽  
Darrell R. Schroeder ◽  
Paul E. Carns ◽  
Jack L. Wilson ◽  
David P. Martin ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Pain Relief ◽  
Celiac Plexus ◽  
Celiac Plexus Block ◽  
Unresectable Pancreatic Cancer ◽  
Plexus Block

Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain

Pain ◽  
1996 ◽  
Vol 64 (3) ◽  
pp. 597-602 ◽  
Author(s):  
Mikito Kawamata ◽  
Kunihiko Ishitani ◽  
Kunitsugu Ishikawa ◽  
Hiromi Sasaki ◽  
Koichi Ota ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Cancer Pain ◽  
Celiac Plexus ◽  
Celiac Plexus Block ◽  
Morphine Treatment ◽  
Plexus Block

scholarly journals EUS-Guided Celiac Plexus Interventions

2020 ◽  
Vol 11 (03) ◽  
pp. 177-181
Author(s):  
Zubin Dev Sharma ◽  
Rinkesh Kumar Bansal ◽  
Rajesh Puri
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Chronic Pancreatitis ◽  
Pain Control ◽  
Celiac Plexus ◽  
Celiac Plexus Block ◽  
Gall Bladder Carcinoma ◽  
Plexus Block

AbstractEndoscopic ultrasound (EUS)-guided celiac plexus intervention comprises EUS-guided celiac plexus block (EUS-CPB) and EUS-guided celiac plexus neurolysis (EUS-CPN). EUS-CPB and EUS-CPN are one of the used methods of pain management in patients of pancreatic cancer and chronic pancreatitis, respectively, along with medical therapy. Both the procedures are associated with minimal complications and improves quality of life. The role of EUS-guided celiac plexus intervention is increasing in gall bladder carcinoma for pain control.

scholarly journals Celiac Plexus Block and Neurolysis in the Management of Chronic Upper Abdominal Pain

2017 ◽  
Vol 34 (04) ◽  
pp. 376-386 ◽  
Author(s):  
Joshua Cornman-Homonoff ◽  
Daniel Holzwanger ◽  
Kyungmouk Lee ◽  
David Madoff ◽  
David Li
Keyword(s):  
Quality Of Life ◽  
Abdominal Pain ◽  
Side Effects ◽  
Celiac Trunk ◽  
Celiac Plexus ◽  
Opiate Dependence ◽  
Celiac Plexus Block ◽  
Upper Abdominal ◽  
Plexus Block

AbstractChronic upper abdominal pain occurs as a complication of various malignant and benign diseases including pancreatic cancer and chronic pancreatitis, and when present may contribute to lower quality of life and higher mortality. Though various pain management strategies are available as part of a multimodal approach, they are often incompletely effective and accompanied by side effects. Pain originating in upper abdominal viscera is transmitted through the celiac plexus, which is an autonomic plexus located in the retroperitoneum at the root of the celiac trunk. Direct intervention at the level of the plexus, referred to as celiac plexus block or neurolysis depending on the injectate, is a minimally invasive therapeutic strategy which has been demonstrated to decrease pain, improve function, and reduce opiate dependence. Various percutaneous techniques have been reported, but, with appropriate preprocedural planning, use of image guidance (usually computed tomography), and postprocedural care, the frequency and severity of complications is low and the success rate high regardless of approach. The main benefit of the intervention may be in reduced opiate dependence and opiate-associated side effects, which in turn improves quality of life. Celiac plexus block and neurolysis are safe and effective treatments for chronic upper abdominal pain and should be considered early in patients experiencing such symptoms.

Referral of Patients With Pain From Pancreatic Cancer for Neurolytic Celiac Plexus Block

1997 ◽  
Vol 72 (9) ◽  
pp. 831-834 ◽  
Author(s):  
David L. Brown ◽  
Renee E. Caswell ◽  
Gilbert Y. Wong ◽  
Lee A. Nauss ◽  
Kenneth P. Offord
Keyword(s):  
Pancreatic Cancer ◽  
Celiac Plexus ◽  
Celiac Plexus Block ◽  
Plexus Block

Celiac plexus radiosurgery for pain management in advanced cancer patients: An international phase II trial.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. TPS466-TPS466
Author(s):  
Yaacov Richard Lawrence ◽  
Tikva Meron ◽  
Adam P. Dicker ◽  
Camilla Zimmermann ◽  
Maoz Ben-Ayun ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pancreatic Cancer ◽  
Clinical Trial ◽  
Cancer Patients ◽  
Short Form ◽  
Pilot Trial ◽  
Celiac Plexus ◽  
High Dose ◽  
Analgesic Use

TPS466 Background: Many cancer patients, especially those with pancreatic cancer, suffer from severe back/epigastric pain. Contemporary approaches (opioids, celiac blocks, systemic chemotherapy) are often inadequate. This clinical trial investigates a new approach in which high-dose radiation (radiosurgery) is focused on the retroperitoneal celiac plexus nerve bundle. Preliminary results from a single institution pilot trial NCT02356406 are promising: pain relief is substantial and side effects minimal. The main aim of the trial is to establish safety/efficacy in the setting of an international multicenter study. Exploratory analyses will examine the relationship between pain reduction and subjects’ quality-of-life, functionality, and caregiver burden. Methods: Eligibility criteria include a diagnosis of metastatic/unresectable malignancy, uncontrolled pain defined as ≥ 5 on 11-point BPI-SF scale despite analgesic use, typical retroperitoneal pain syndrome, prognosis > 8 weeks, ECOG 0-2, anatomical involvement of the celiac plexus (e.g. any pancreatic cancer, or any other cancer involving the celiac trunk). Exclusion criteria include previous upper abdo. radiation. The intervention consists of a single 25 Gy radiation fraction delivered to the celiac plexus, using anterolateral aspect of the aorta from the 12th thoracic to 2nd lumbar vertebral body as a surrogate structure. The primary tumour may be irradiated at physicians’ discretion. Dose-painting technique limits dose to organs at risk. Pain intensity will be measured using Brief Pain Inventory Short Form (BPI-SF), and quality of life with FACT-Hep. The primary endpoint is complete or partial pain response, defined as a decrease between the score immediately before treatment and 3 weeks’ post-treatment. A change of two or more on the BPI 11-point pain scale is defined as clinically significant. Secondary endpoints include other BPI pain endpoints, pain at 6 weeks, analgesic use, toxicity (CTCAE v4.03), quality of life and functional measures. Analgesia is not restricted. Expected accrual is 100 subjects over three years. Supported by Gateway for Cancer Research, additional support from Israel Cancer Association. Clinical trial information: NCT03323489.

Sign in / Sign up

Export Citation Format

Share Document